Skip to main content
Fig. 2 | Respiratory Research

Fig. 2

From: Long-term evaluation of the safety and efficacy of recombinant human pentraxin-2 (rhPTX-2) in patients with idiopathic pulmonary fibrosis (IPF): an open-label extension study

Fig. 2

Mean and mean change from baseline in: A percent predicted FVC; B absolute FVC; C 6MWD, over 128 weeks (ATS-OLE population). 6MWD, 6-min walk distance; ATS-OLE, All Treated Set of the open-label extension; CI, confidence interval; FVC, forced vital capacity; rhPTX-2, recombinant human pentraxin-2

Back to article page

Respiratory Research

ISSN: 1465-993X

Contact us